Evidence map›Paper›PMID 19514716›Full record

ArticleBioconjugate chemistry2009

In vivo stable tumor-specific painting in various colors using dehalogenase-based protein-tag fluorescent ligands.

Nobuyuki Kosaka, Mikako Ogawa, Peter L Choyke, Natasha Karassina, Cesear Corona, Mark McDougall, David T Lynch, Clifford C Hoyt, Richard M Levenson, Georgyi V Los and 1 more

Open access · greenAbstract read
In one paragraph

Article in Bioconjugate chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Nobuyuki KosakaMolecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bldg. 10, Room 1B40, MSC 1088, 10 Center Drive, Bethesda, Maryland 20892-1088, USA.
Mikako Ogawa
Peter L Choyke
Natasha Karassina
Cesear Corona
Mark McDougall
David T Lynch
Clifford C Hoyt
Richard M Levenson
Georgyi V Los
Hisataka Kobayashi
Promega (United States) · USCenter for Cancer Research · USCabot (United States) · USNational Cancer Institute · US

Funding

Growth Factor Imaging and PhotoimmunotherapyZIABC010656 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2024
$31.6M
Intracellular In vivo ImagingZIABC010657 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$20.3M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

In vivo fluorescence cancer imaging is an important tool in understanding tumor growth and therapeutic monitoring and can be performed either with endogenously produced fluorescent proteins or with exogenously introduced fluorescent probes bound to targeting molecules. However, endogenous fluorescence proteins cannot be altered after transfection, thus requiring rederivation of cell lines for each desired color, while exogenously targeted fluorescence probes are limited by the heterogeneous expression of naturally occurring cellular targets. In this study, we adapted the dehalogenase-based protein-Tag (HaloTag) system to in vivo cancer imaging, by introducing highly expressed HaloTag receptors (HaloTagR) in cancer cells coupled with a range of externally injected fluorophore-conjugated dehalogenase-reactive reactive linkers. Tumor nodules arising from a single transfected cell line were stably labeled with fluorescence varying in emission spectra from green to near-infrared. After establishing and validating a SHIN3 cell line stably transfected with HaloTagR (HaloTagR-SHIN3), in vivo spectral fluorescence imaging studies were performed in live animals using a peritoneal dissemination model. The tumor nodules arising from HaloTagR-SHIN3 could be successfully labeled by four different fluorophore-conjugated HaloTag-ligands each emitting light at different wavelengths. These fluorophores could be alternated on serial imaging sessions permitting assessment of interval growth. Fluorescence was retained in histological specimens after fixation. Thus, this tagging system proves versatile both for in vivo and in vitro imaging without requiring modification of the underlying cell line. Thus, this strategy can overcome some of the limitations associated with the use of endogenous fluorescent proteins and exogenous targeted optical agents in current use.

Indexed as

AnimalsBinding SitesCell Line, TumorDiagnostic ImagingEndoscopyFemaleFluorescenceFluorescent DyesGene ExpressionHumansLigandsMiceOvarian NeoplasmsProteinsTransfectionFluorescent DyesLigandsProteins

Identifiers

PMID19514716
PMCPMC2841743
OpenAlexW1985801809

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.